ProCE Banner Activity

ALEXANDRA/IMpassion030: Phase III Trial of Adjuvant Chemotherapy ± Atezolizumab for Stage II/III Triple-Negative Breast Cancer

Conference Coverage

In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to adjuvant chemotherapy did not improve iDFS over chemotherapy alone, according to results of the phase III ALEXANDRA/IMpassion030 trial.

Released: December 08, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.